Accessibility Menu
Gamida Cell logo

Gamida Cell

(OTC) GMDA

This security has been delisted. This page is retained for historical reference.

Gamida Cell last closing stock price
MetricPriceDate
Last closeUSD 0.022024-05-24
Gamida Cell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.66%USD 0.022024-05-17
1 month+9.68%USD 0.022024-04-24
3 month-94.97%USD 0.342024-02-23
Year to date-95.88%USD 0.412023-12-29
1 year-99.14%USD 1.982023-05-25
3 year-99.71%USD 5.852021-05-25
5 year-99.76%USD 7.192019-05-24
Since inception-99.8%USD 8.442018-10-26

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

GMDA Financials

Key Financial Metrics (TTM)

Gross Margin

-94.96%

Operating Margin

-4094.06%

Net Income Margin

-3531.17%

Return on Equity

1148.30%

Return on Capital

-91.30%

Return on Assets

-61.65%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$3.50M

Operating Income

-$33.12M

EBITDA

-$75.15M

Operating Cash Flow

-$79.04M

Capital Expenditure

-$331.33K

Free Cash Flow

-$79.37M

Cash & ST Invst.

$24.78M

Total Debt

$78.09M

Gamida Cell Performance Analysis

Gamida Cell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 1,784,000N/A
Gamida Cell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30N/A
Q32023-09-30N/A
Q42023-12-3165.1%
Q12024-03-31-19.9%
Gamida Cell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.52N/A
20222022-12-31USD -1.24-17.9%
20232023-12-31USD -0.57-54.0%
Gamida Cell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30-6.9%
Q32023-09-3096.1%
Q42023-12-31-401.6%
Q12024-03-31312.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$890.00K

N/A

Gross Profit

-$2.72M

-2464.2%

Gross Margin

-3.05%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

143

N/A

Net Income

$19.95M

+189.3%

EBITDA

-$24.01M

-23.3%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$24.78M

-47.0%

Total Debt

$78.09M

-18.4%

Accounts Receivable

$1.03M

N/A

Inventory

$1.97M

N/A

Long Term Debt

$1.85M

-98.0%

Short Term Debt

$76.24M

+1730.9%

Return on Assets

-61.65%

N/A

Return on Invested Capital

-94.87%

N/A

Free Cash Flow

-$23.09M

+0.1%

Operating Cash Flow

-$23.00M

-3.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBRVFNabriva Therapeutics plc
$0.00+0.00%
TNFATNF Pharmaceuticals, Inc.
$5.20+48.15%
NEUPNeuphoria Therapeutics Inc.
$3.53+0.28%
HILSHillstream BioPharma, Inc.
$0.24+5.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
NOKNokia
$10.38-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.74-0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.89+0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.